ICICI Direct has given Hold recommendation for Alembic Pharma with a target price of Rs. 885 in its research report issued on Jul 27, 2021

ICICI Direct’s research report on Alembic Pharma

Alembic Pharma operates in international generics (54%), domestic branded (28%) and API (18%).Exports contribute 69% of sales (US~74%), domestic contributes 31% of sales (Chronic~69% & Acute~31%) It has filed 212 ANDA and has 146 approvals with 94 product launches

Outlook 

We maintain our HOLD rating on the stock  We value Alembic at Rs 885 i.e. 20x P/E on FY23E EPS

 

Leave a Reply

Your email address will not be published. Required fields are marked *